US stocks looked set to open higher Friday as investors parsed key inflation data that matched analyst forecasts.

Dow Jones Industrial Average futures were up 0.49%, S&P 500 futures gained 0.29%, and Nasdaq futures edged 0.10% higher.

Oil prices were moving lower, with front-month global benchmarks Brent crude and West Texas Intermediate crude declining 1.05% and 1.21% respectively.

The January core personal consumption price index slowed to an annual rate of 2.6% from 2.9% the previous month, meeting analyst forecasts, according to Bloomberg. The monthly core PCE prince index rose by 0.3% in January from 0.2% in December, also as expected.

In other world markets, Japan's Nikkei tumbled 2.88%, Hong Kong's Hang Seng plummeted 3.28%, and China's Shanghai Composite fell 1.98%. In Europe's early afternoon session, the UK's FTSE 100 was up 0.38%, while Germany's DAX and France's CAC 40 dropped 0.51% and 0.46%, respectively.

Among gaining stocks, Interactive Strength (TRNR) jumped 32%, adding to a 22% gain on Thursday. BioXcel Therapeutics (BTAI) gained 17% after it said Friday that it has regained compliance with Nasdaq's minimum closing bid price requirement. OneConnect Financial Technology (OCFT) advanced 18% after a 4% loss the previous session. And Organogenesis (ORGO) shares climbed 18%, after a 5.5% loss on Thursday.

On the losing side, shares of DocGo (DCGO) tumbled 22% after Deutsche Bank downgraded the company's stock Friday to hold from buy, and lowered its price target to $2.85 From $5. Mustang Bio (MBIO) dropped 26% after it said after hours on Thursday that it has exited the lease for its manufacturing facility in Worcester, Massachusetts and divested certain fixed assets. Iovance Biotherapeutics (IOVA) shares dropped 23% after losing 1.7% on Thursday. DLocal (DLO) shed 25% after it reported late Thursday that its Q4 earnings and revenue missed analyst forecasts. And NetApp (NTAP) shares were down 17%, after reporting late Thursday lower fiscal Q3 non-GAAP earnings and cutting its fiscal 2025 non-GAAP EPS guidance.